In addition, the anti-TNF-α agents, such as infliximab and adalimumab, potently suppressed IL-12/IL-23 production by inflammatory macrophage by activating FcγRs (47), but anti-TNF-α agent did not play a beneficial effect for development of cirrhosis (48). This evidence concerns the gene TNF and Cirrhosis.